

Señor

SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. _____ S. _____ D. _____

Re: **P1. MERCK & CO, INC.- Solicitud de Patente de Invención**
Fase Nacional PCT para "COMPUESTOS PARA EL
TRATAMIENTO DEL ÁNTRAX E INHIBIDORES DEL
FACTOR LETAL".- Clase A61K 31/00.- Expediente número
04-118.236.-

1. Me refiero a mi solicitud de patente PCT presentada el 24 de Noviembre de 2004.

2. Por medio del presente me permito manifestar a usted que es deseo del solicitante modificar el preámbulo de la reivindicación 9 con el fin de subsanar un error de transcripción cometido en el momento de presentación de la solicitud. En este sentido la nueva reivindicación 9 debe leerse: **"9. Una composición que comprende un compuesto de fórmula I de acuerdo con la reivindicación 1, y un transportador farmacéuticamente aceptable".**

Sobre este particular, atentamente me permito manifestar que la anterior modificación **no amplía** de ninguna manera el alcance de la presente solicitud, toda vez que la misma solamente obedece a distinguir de manera más clara y precisa las enseñanzas de la presente invención y a proteger un objeto específico que se encuentra incluido dentro de dichas enseñanzas.

3. Anexo me permito presentar:

(a) Recibo número 04-91,035, expedido por la Superintendencia de Industria y Comercio, que acredita el pago de la modificación mencionada;

(b) Formulario de correcciones y modificaciones; y

- (c) Copia de las páginas 35 a 52 del capítulo reivindicatorio, que reemplazan a las originalmente presentadas mediante mi solicitud de 24 de Noviembre de 2004, en las cuales se ha realizado la modificación expuesta anteriormente.

4. En vista de todo lo anterior, ruego a usted proceder a estudiar de conformidad la presente solicitud y conceder el privilegio de patente solicitado.

Señor Superintendente,


ALICIA LLOREDA RICAURTE
T.P. 53.215

NIT : 800174089-2

RECIBO OFICIAL DE CAJA : 04 - 91,035
FECHA : NOVIEMBRE 24 DE 2004


***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
LLOREDA Y CIA S. A	CONSIGNACION	BANCO POPULAR	050-00110-6	23713715	24/11/2004	3,395,000.00

***** CONCEPTO *****

CANT. RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1 50005-01-03 CAMBIO DE MODALIDAD Y MODIFICA	12 MARCAS Y LEMAS COMERCIALES	87,000.00
	TOTAL :	\$ 97,000.00

SON: OCHENTA Y SIETE MIL PESOS

RESPONSABLE : _____ 

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

FORMULARIO ÚNICO DE CORRECCIONES Y MODIFICACIONES.
2000-10

①

SOLICITUD DE:



Corrección de Error Material.



Modificación a una Solicitud.

②

SOLICITANTE

Nombre: **MERCK & CO., INC.**

Dirección: 128 East Lincoln Avenue, Rahway, Estado de New Jersey 07085-0907, Estados Unidos de América.

Teléfono: 3 284270

Fax: 6 069701

E-mail: jllcco@lloredacamacho.com

Domicilio: Rahway, Estado de New Jersey, Estados Unidos de América.

IDENTIFICACION

C.C. ☐

NIT ☐

C.E. ☐

Otro ☐

Número _____

③

**REPRESENTANTE
O APODERADO**

Nombre: **ALICIA LLORED A RICAURTE**

Dirección: Calle 72 No. 5-83 Piso 5, Bogotá, Colombia

Teléfono: 3 284270

Fax: 6 069701

E-mail: jllcco@lloredacamacho.com

IDENTIFICACION

C.C. ☒

NIT ☐

C.E. ☐

Otro ☐

Número 39.690.713 TP 53.215

④

Número de expediente:

04-118.236

⑤

Descripción de la corrección o modificación solicitada corrección de transcripción de la
reivindicación 9.

⑥

Comprobante de pago No. 04-91,035

Fecha 24 de Noviembre de 2004

⑦

Anexos:



Comprobante de pago de la tasa.



Poderes, si fuere el caso.



Certificado de existencia y representación legal de las partes, cuando sean personas jurídicas.

⑧

NOMBRE ALICIA LLORED A RICAURTE

FIRMA




C.C. 39.690.713

T.P. 53.215

REIVINDICACIONES:

1. Un compuesto de fórmula I:



FORMULA I

O una sal farmacéuticamente aceptable, enantiómero, diastereómero o éster hidrolizable in vivo o mezcla de ellos, donde,

- 10 R^1 representa C₆-10 aril, C₅-10 heteroaril o C₅-10 heterocíclico, dicho aril, heteroaril y heterociclil opcionalmente substituido con de 1 a 3 grupos de R^a


R^a representa C₁-6 alquil, halógeno, OH, aril(C₁-6)alquil, (C₁-6)alcoxi, (C₁-6)alcoxi(C₁-6)alquil, halo(C₁-6)alquil, nitro, amino, mono- o di-N-(C₁-

- 15 6)alquilamino, acilamino, aciloxi, carboxi, carboxi sales, carboxi ésteres, carbamoil, mono- y di-N-(C₁-6)alquilcarbamoil, (C₁-6)alcoxycarbonil, ariloxycarbonil, ureido, guanidino, sulfonilamino, aminosulfonil, (C₁-6)alquiltio, (C₁-6)alquilsulfinil, (C₁-6)alquilsulfonil, heterociclil, heterociclil(C₁-6)alquil; y

- 20 R representa C₁-8 alquil, C₃-10 cicloalquil, C₃-10 heterocicloalquil, C₅-10 heteroaril, o C₅-11 heterociclil, dicho heteroaril y heterociclil opcionalmente substituido con de 1 a 3 grupos de R^a y dicho alquil, opcionalmente substituido con de 1 a 3 grupos seleccionados del grupo consistente en aril, heterociclil, (C₁-6)alquiltio, ciano, heteroaril, guanidino, ((1-aminoetil)carbonil)amino, ((aminometil)carbonil)amino, ((2-amino)prop-2-il) carbonil)amino, acetamido, 4-(aminometil)fenil, tio, t-butil sulfonil, (C₂-6)alqueniltio, (C₂-6)alquiniltio, amino, mono- o di-(C₁-6)alquilamino, ariltio, heterociciltio, (C₁-6)alcoxi, aril(C₁-6)alcoxi, aril(C₁-6)alquiltio, cicloalquil, cicloalquenil, carboxi y ésteres de ellos, hidroxil y halógenos.


















- 30 2. Un compuesto según la reivindicación 1 donde R es un heterocicloalquilo y todas las demás variables como se definieron originalmente.

3. Un compuesto según la reivindicación 1 donde R es un heteroaril y todas las demás variables como se definieron originalmente.
4. Un compuesto según la reivindicación 1 donde R¹ es un grupo fenil opcionalmente sustituido con de 1 a 3 grupos de R^a y R es un grupo heterocicloalquil, o heteroaril.
5. Un compuesto según la reivindicación 1 donde R¹ es un grupo fenil opcionalmente sustituido con de 1 a 3 grupos entre metoxi, halógeno, metil, etil, propil, butil, naftil, 5-(2-piridil)tiofen-2-il o una mezcla de ellos, y R un heterocicloalquilo o heteroarilo.
6. Un compuesto según la reivindicación 1 el cual es seleccionado del grupo consistente en:
 - 15 N-t-butoxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-metilbutiramida;
 - N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-metilbutiramida;
 - N-t-butoxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-2-(4'-tetrahidropiranyl)-acetamida;
 - N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-2-(4'-tetrahidropiranyl)-acetamida;
 - 20 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-(S)-ciclopropilbutiramida; y
 de las tablas 1 y 2 siguientes





































25




















Ejemplo #	R1	R2
3		



















4		
5		
6		
7		
8		
9		
10		
11		
12		


















13		
14		
15		
16		
17		
18		
19		
20		
21		
22		



















23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		



















34		
35		
36		
37		
38		
39		
40		
41		
42		
43		



















44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		


















55		
56		
57		
58		
59		
60		
61		
62		
63		
64		



















65		
66		
67		
68		
69		
70		
71		
72		
73		
74		



















75		
76		
77		
78		
79		
80		
81		
82		
83		
84		

85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		

96		
97		
98		
99		
100		
101		
102		
103		
104		

105		
106		
107		
108		
109		
110		
111		
112		
113		
114		

115		
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		

127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		

















139		
140		
141		
142		
143		
144		

Tabla 2



Ejemplo #	R1	R2
146		Me
147		Me

148		Me
149		H
150		Me
151		Me
152		Me
153		Me

y sales farmacéuticamente aceptables, enantiómeros, diastereómeros o ésteres hidrolizables in vivo o mezclas de ellos.

7. Un compuesto de acuerdo con la reivindicación 6 el cual se selecciona del grupo consistente en:
- 5 N-t-butoxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-metilbutiramida;
 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-metilbutiramida;
 N-t-butoxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-2-(4'-tetrahidropiranyl)-acetamida;
- 10 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-2-(4'-tetrahidropiranyl)-acetamida;
 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-(S)-ciclopropilbutiramida; y
 sales farmacéuticamente aceptables, enantiómeros, diastereómeros o ésteres hidrolizables in vivo o mezclas de ellos.

15

8. Un compuesto de acuerdo con la reivindicación 7 el cual es:
 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-3-metilbutiramida; o
 N-hidroxi-2(R)-[(4-fluoro-3-metilfenilsulfonil)]amino-2-(4'-tetrahidropiranyl)-acetamida; o sales farmacéuticamente aceptables, enantiómeros, diastereómeros o
 20 ésteres hidrolizables in vivo o mezclas de ellos.

9. Una composición que comprende un compuesto de fórmula I de acuerdo con la reivindicación 1, y un transportador farmacéuticamente aceptable.

5

10

15

20

25

30

35